Close
Help
Need Help?





JOURNAL

Clinical Medicine Insights: Oncology

893,463 Journal Article Views | Journal Analytics

Antitumor Efficacy of Intravesical BCG, Gemcitabine, Interferon-α and Interleukin-2 as Mono- or Combination-Therapy for Bladder Cancer in an Orthotopic Tumor Model

Submit a Paper



Publication Date: 21 Sep 2011

Type: Original Research

Journal: Clinical Medicine Insights: Oncology

Citation: Clinical Medicine Insights: Oncology 2011:5 315-323

doi: 10.4137/CMO.S7658

Abstract

Objective: To reduce adverse effects and improve efficacy of intravesical BCG for bladder cancer, alternative treatment options were investigated in an orthotopic rat tumor model.

Methods: Superficial bladder cancer was established in syngeneic female rat bladders by instillation of AY-27 cells. Animals were randomly assigned to treatment groups including dose escalation of intravesical BCG with or without interferon-α (IFN-α) or interleukin-2 (IL-2); or graded doses of gemcitabine alone; or BCG plus gemcitabine. Treatments were given twice weekly for 3 weeks. Rats in control groups received saline instillations. Treatment response was monitored by animals’ well-being, survival days, tumor growth inhibition, and histological examination at necropsy.

Results: Rats receiving monotherapy with intravesical BCG, gemcitabine, or IFN-α, attained significantly better survival and tumor reduction compared with control (P = 0.002; 0.001; 0.002, respectively, Log-rank Test). A dose-dependent treatment response was observed in animals with established bladder tumor receiving escalated BCG instillations. Only high-dose BCG significantly improved animal survival. Although high-dose BCG plus gemcitabine or IFN-a did not increase benefit over monotherapies, low-dose BCG plus IL-2 did show improved efficacy (P = 0.01).

Conclusion: Intravesical monotherapies with gemcitabine and IFN- were as effective as BCG for treatment of early non-muscle-invasive urothelial bladder cancer in this immune competent rat model. Combining these agents with high-dose BCG did not further increase efficacy. However, combining low-dose BCG with IL-2 enhanced BCG effectiveness.


Downloads

PDF  (1.45 MB PDF FORMAT)

RIS citation   (ENDNOTE, REFERENCE MANAGER, PROCITE, REFWORKS)

BibTex citation   (BIBDESK, LATEX)

XML






What Your Colleagues Say About Clinical Medicine Insights: Oncology
We have had a fantastic and unprecedented experience publishing our paper in Clinical Medicine Insights: Oncology.  The process of submitting and correcting the proofs were simple, quick, and smooth.  We appreciated the clarity and easiness of instructions and your fast responses to our emails. Great work.  Keep it up.
Dr Sabri Sanabani (Hemocentro de São Paulo, Brazil)
More Testimonials

Quick Links




Follow Us We make it easy to find new research papers.




SUBJECT HUBS
Author Survey Results
author_survey_results
All authors are surveyed after their articles are published. Authors are asked to rate their experience in a variety of areas, and their responses help us to monitor our performance. Presented here are their responses in some key areas. No 'poor' or 'very poor' responses were received; these are represented in the 'other' category.
See Our Results